Puridify aims to develop bioprocessing technologies to significantly advance industrial biomolecule manufacture.
Global demand for cheaper biotherapeutics, which represent many of the new tools in the fight against diseases such as cancer and neurodegenerative conditions, drives the need for increased efficiency in biomolecule manufacturing. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. Puridify is developing and commercialising innovative bioprocessing platform technologies, allowing the cost effective manufacture of a wide range of existing and new biomolecule products.
Our company is privately funded by leading venture capital investors. Puridify’s head office and research & development facilities are based at Stevenage Bioscience Catalyst, 20 minutes north of London.We work closely with bioprocessing research experts at University College London and many leading industrial collaborators around the world to drive our rapid development.